Cargando…

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution

Panitumumab (Pmab) is generally considered to be ineffective after the failure of cetuximab (Cmab) therapy in metastatic colorectal cancer (mCRC) patients. However, a few studies have demonstrated that Pmab is an effective treatment for disease progression following Cmab-based regimens in the USA. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	SONODA, HIROMICHI, MEKATA, EIJI, SHIMIZU, TOMOHARU, ENDO, YOSHIHIRO, TANI, TOHRU
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628964/ https://www.ncbi.nlm.nih.gov/pubmed/23599789 http://dx.doi.org/10.3892/ol.2013.1171

Ejemplares similares

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
por: Sonoda, Hiromichi, et al.
Publicado: (2014)

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
por: MEKATA, EIJI, et al.
Publicado: (2013)

Differences in Chemosensitivity between Primary and Metastatic Tumors in Colorectal Cancer
por: Takebayashi, Katsushi, et al.
Publicado: (2013)

Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II–III colorectal cancer
por: MEKATA, EIJI, et al.
Publicado: (2013)

Successful surgical approach for a patient with encapsulating peritoneal sclerosis after hyperthermic intraperitoneal chemotherapy: a case report and literature review
por: Takebayashi, Katsushi, et al.
Publicado: (2014)

Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review
por: Takebayashi, Katsushi, et al.
Publicado: (2016)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
por: Kasagi, Yuta, et al.
Publicado: (2013)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: da Silva, Wânia Cristina, et al.
Publicado: (2018)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Fibrosis in metastatic lymph nodes is clinically correlated to poor prognosis in colorectal cancer
por: Ikuta, Daiji, et al.
Publicado: (2018)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

Anti-endotoxin Properties of Polymyxin B-immobilized Fibers
por: Tani, Tohru, et al.
Publicado: (2019)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
por: Xu, Yifan, et al.
Publicado: (2018)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer
por: Koumaki, Dimitra, et al.
Publicado: (2020)

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
por: Zhou, Si-wei, et al.
Publicado: (2012)

EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
por: Jiang, Zheng, et al.
Publicado: (2013)

Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma
por: Chen, Jianxin, et al.
Publicado: (2020)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery
por: Ohta, Hiroyuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dcolbjtrdbqkudmfas4gk9kp8b